Clinical Trial Search

Primary: Part 1: Number of Participants With Any Adverse Events (AEs) and by Severity — 4; 2; 3; 0 Participants

Primary: Number of Treatment-Emergent Adverse Events (Safety and Tolerability) — 34; 54; 51; 20 Number of TEAEs

Primary: Number of Participants With Treatment-Emergent Adverse Events Including SAEs [Safety and Tolerability] of NOX66 Combined With Radiation Therapy at Multiple Timepoints…

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 6; 0; 0; 0 Participants

Primary: Urinary and Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 90.2 percentage of administered radioactivity

Primary: Part 1: Maximum Tolerated Dose (MTD) of BI 836845 During the First Treatment Course of the Dose Escalation Phase. — 1000 milligram (mg)

Primary: Objective Response Rate (ORR) in Abemaciclib Arm (Arm 1) — 0 Participants

Primary: Incidence of Treatment Emergent Adverse Events — 2; 2; 0; 3 participants

Primary: Safety and Tolerability — 7; 8; 12; 3 AEs

Primary: Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using Vial and PFS by HCP — 9954.89; 10163.74 Nanograms per milliliters (ng/mL)

Primary: Intraocular Pressure (IOP) Increment — 14.00; 13.57; 13.47; 13.25 mmhg

Primary: Incidence of Related Unexpected Adverse Events (AE) — 12 Number of unexpected related AE

Primary: Retention Rate — 91.7 percentage of Participants

Primary: Phase Ib Escalation Part: Number of Patients With Dose Limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057